Cardizem La

Angina Pectoris, Variant, Atrial Fibrillation, Proteinuria + 11 more

Treatment

6 FDA approvals

20 Active Studies for Cardizem La

What is Cardizem La

Diltiazem

The Generic name of this drug

Treatment Summary

Diltiazem is a drug used to lower blood pressure and treat certain heart conditions. It belongs to a class of drugs called calcium channel blockers and works by preventing calcium from entering the heart and blood vessels, which relaxes the muscles and lowers the pressure. Diltiazem is available in both an oral and intravenous form and is sold under the brand names Cardizem and Tiazac. It is commonly used to treat high blood pressure, irregular heartbeats, and chest pain. It can also be used to treat anal fissures, migraines, pulmonary hypertension, and rest-related cramps.

Cardizem

is the brand name

Cardizem La Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Cardizem

Diltiazem

1982

656

Approved as Treatment by the FDA

Diltiazem, commonly known as Cardizem, is approved by the FDA for 6 uses which include Coronary Vasospasm and Coronary Artery Vasospasm .

Coronary Vasospasm

Helps manage Coronary Artery Vasospasm

Coronary Artery Vasospasm

Helps manage Coronary Artery Vasospasm

Anginal Pain

Helps manage Anginal Pain

Hypertensive disease

Helps manage High Blood Pressure (Hypertension)

Angina, Stable

Helps manage Chronic Stable Angina Pectoris

Angina Pectoris

Helps manage Anginal Pain

Effectiveness

How Cardizem La Affects Patients

Diltiazem is a medication that lowers blood pressure and relaxes the blood vessels. It does this by blocking calcium from entering the muscle cells of the heart and blood vessels. By doing this, it helps reduce the risk of stroke and heart attack. In studies, taking diltiazem was found to lower the diastolic blood pressure by up to 8.6 mmHg in people with high blood pressure, and improved exercise tolerance in those with chronic stable angina. It has also been suggested that diltiazem may provide a protective effect against stroke in those with hypertension.

How Cardizem La works in the body

Diltiazem works by blocking calcium from entering the cells in the heart and blood vessels. This reduces the amount of calcium available in the cells and allows the muscles to relax. As a result, blood pressure decreases, oxygen delivery to the heart increases, and the heart's workload is reduced. This leads to improved exercise tolerance and improved heart health.

When to interrupt dosage

The advocated measure of Cardizem La is dependent upon the diagnosed illness, including prophylaxis of migraine headaches, Fissure;Anal and Anginal Pain. The amount of dosage fluctuates as per the delivery approach noted in the table beneath.

Condition

Dosage

Administration

Angina Pectoris

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Atrial Fibrillation

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Coronary Vasospasm

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Angina Pectoris, Variant

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Proteinuria

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Hypertensive disease

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Angina, Stable

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Tachycardia, Supraventricular

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Cardiomyopathy, Dilated

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Migraine Disorders

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Diabetic Neuropathy

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Pulmonary Hypertension

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Fissure in Ano

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Muscle Cramp

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Warnings

Cardizem La has ten contraindications, thus should not be utilized when encountering any of the conditions in the following table.

Cardizem La Contraindications

Condition

Risk Level

Notes

Heart Attack

Do Not Combine

accessory bypass tract

Do Not Combine

accessory bypass tract

Do Not Combine

Bradycardia

Do Not Combine

Ventricular Tachycardia

Do Not Combine

Bradycardia

Do Not Combine

Atrioventricular Block

Do Not Combine

Pulmonary Congestion

Do Not Combine

Shock, Cardiogenic

Do Not Combine

Hypotension

Do Not Combine

There are 20 known major drug interactions with Cardizem La.

Common Cardizem La Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The metabolism of Abemaciclib can be decreased when combined with Diltiazem.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be decreased when combined with Diltiazem.

Alectinib

Major

The metabolism of Alectinib can be decreased when combined with Diltiazem.

Alfentanil

Major

The metabolism of Alfentanil can be decreased when combined with Diltiazem.

Amifostine

Major

Diltiazem may increase the hypotensive activities of Amifostine.

Cardizem La Toxicity & Overdose Risk

Diltiazem is toxic when taken in large doses. The toxic dose in mice is between 415-740mg/kg, in rats between 560-810mg/kg and in dogs over 50 mg/kg. In monkeys, a dose of 360 mg/kg was fatal. Reports of diltiazem overdose range from less than 1g to 18g. Symptoms include slowed heart rate, low blood pressure, heart blockage, and heart failure which can lead to dizziness, fatigue, and lightheadedness. Treatment includes administering atropine, isoproterenol, or cardiac pacing to treat bradycardia or

image of a doctor in a lab doing drug, clinical research

Cardizem La Novel Uses: Which Conditions Have a Clinical Trial Featuring Cardizem La?

Currently, there are 228 active trials investigating the potential of Cardizem La to alleviate Atrial Fibrillation, Coronary Artery Spasm and Paroxysmal Supraventricular Tachycardia (PSVT).

Condition

Clinical Trials

Trial Phases

Atrial Fibrillation

90 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Phase 1, Phase 3, Early Phase 1

Diabetic Neuropathy

6 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Pulmonary Hypertension

33 Actively Recruiting

Phase 2, Phase 3, Not Applicable, Phase 1, Early Phase 1

Tachycardia, Supraventricular

2 Actively Recruiting

Phase 3, Phase 2

Angina, Stable

0 Actively Recruiting

Angina Pectoris, Variant

0 Actively Recruiting

Angina Pectoris

2 Actively Recruiting

Not Applicable, Phase 4

Cardiomyopathy, Dilated

1 Actively Recruiting

Not Applicable

Proteinuria

5 Actively Recruiting

Phase 2, Phase 3, Phase 4, Phase 1

Muscle Cramp

0 Actively Recruiting

Hypertensive disease

27 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3

Coronary Vasospasm

0 Actively Recruiting

Migraine Disorders

1 Actively Recruiting

Phase 3

Fissure in Ano

0 Actively Recruiting

Cardizem La Reviews: What are patients saying about Cardizem La?

5

Patient Review

12/4/2008

Cardizem La for High Blood Pressure

5

Patient Review

8/11/2010

Cardizem La for High Blood Pressure

my husband is taking it for hypertension. He's allergic to sulfa, which rules out most blood pressure medications. Lisinopril 20mg isn't doing the trick either; his blood pressure is still high.

4.3

Patient Review

9/6/2008

Cardizem La for Ventricular Rate Control in Atrial Fibrillation

4.3

Patient Review

1/15/2009

Cardizem La for High Blood Pressure

I was prescribed this after I couldn't tolerate metoprolol and bystolic. In the two weeks since I started taking cardizem, I've developed pain in my neck and shoulder on the right side. It's getting worse every day and I have no idea why.

3.7

Patient Review

11/5/2008

Cardizem La for High Blood Pressure

3.7

Patient Review

1/9/2010

Cardizem La for Hypertrophic Cardiomyopathy

This medication got my heart arrhythmia under control quickly. However, after a few months of taking it, the afib has come back and now my blood pressure is very low. I'm going to have to talk to my doctor again about this.

3.7

Patient Review

11/26/2011

Cardizem La for High Blood Pressure

My son takes this for spasms in his esophagus- it relaxes the muscles there so that food can pass through. He has to take it at bedtime because it makes him dizzy, but it works really well!

3

Patient Review

12/28/2008

Cardizem La for Ventricular Rate Control in Atrial Fibrillation

This medication works well for me, as long as I take it before bed. If I miss a day, I experience some pretty intense side effects like rapid heart palpitations and chest pain. So, while it's great for high blood pressure, just be aware that you need to be very consistent with taking it.

2.3

Patient Review

3/14/2009

Cardizem La for High Blood Pressure

I started taking this medication a month ago and last night I started to experience a rash on my legs that has been extremely itchy and swollen.

1

Patient Review

2/13/2008

Cardizem La for High Blood Pressure

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about cardizem la

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What does Cardizem LA stand for?

"Generic diltiazem hydrochloride is a calcium channel blocker used to treat hypertension (high blood pressure), angina (chest pain), and certain heart rhythm disorders."

Answered by AI

What is the difference between Cardizem CD and LA?

"Unlike other diltiazem formulations that are taken once a day, CARDIZEM® LA is a tablet formulation. Its pharmacokinetic profile differs from that of CARDIZEM® CD, another extended-release formulation of diltiazem, in that it has a smoother drug-release profile with a "one-peak" plasma concentration time curve."

Answered by AI

Is Cardizem LA long acting?

"Make sure to tell all of your health care providers that you take Cardizem LA (diltiazem long-acting tablets). This includes your doctors, nurses, pharmacists, and dentists. Avoid driving or doing other tasks that require you to be alert until you see how Cardizem LA (diltiazem long-acting tablets) affects you."

Answered by AI

Is diltiazem ER the same as Cardizem LA?

"Diltiazem is a medication used to treat high blood pressure and chest pain by relaxing blood vessels and decreasing the workload of the heart. It is part of a group of medications known as calcium channel blockers."

Answered by AI

Clinical Trials for Cardizem La

Image of Miles Square Health Center Chicago in Chicago, United States.

Food is Medicine for High Blood Pressure and Obesity

Any Age
All Sexes
Chicago, IL

The goal of this clinical trial is to treat both hypertension and obesity in adults using a food is medicine framework. Participants will be randomized 1:1 to FIM+DASH or usual-care control. The 24-week trial includes a 12-week FIM+DASH intervention followed by a 12-week maintenance period and leverages existing partnerships with community-based organizations for home food delivery and culinary skill-skill building. The main questions it aims to answer are: (1) What is the effect of FIM+DASH vs. usual care control on blood pressure? (2) What is the effect of FIM+DASH vs. usual care control on DASH diet adherence (diet quality), body weight, and waist circumference? (3) How to identify factors associated with the sustainability and scalability of FIM+DASH in real-world settings?

Phase 2
Waitlist Available

Miles Square Health Center Chicago (+3 Sites)

Image of Northwestern University in Chicago, United States.

Exercise Program for Atrial Fibrillation and Heart Failure

60 - 99
All Sexes
Chicago, IL

Atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) are very common conditions that often occur together and result in worsening symptoms and reduced quality of life (QoL). Limitations being able to participate in activities of daily living is a primary complaint for AF-HFpEF patients, yet effective strategies to address this issue remain limited. While exercise interventions targeting aerobic training (AT) are recommended for patients with AF and HFpEF, unique challenges exist in this patient population who tend to be older. Specifically, many older patients with AF and HFpEF have muscle weakness, sarcopenia and frailty, that can make aerobic-focused exercise difficult and less tolerable. This study proposes that starting with progressive resistance training (PRT) before aerobic exercise may overcome these issues by improving muscle strength, making AT more manageable, and leading to better health outcomes. The goal of this study is to assess whether a sequential exercise program, named 'PREACTIVE' improves how people feel, decrease the amount of symptoms, and their ability to participate in exercise and activities. This study will specifically test a sequenced exercise approach of resistance training followed by aerobic exercise to improve symptoms, and quality of life in AF-HFpEF.

Waitlist Available
Has No Placebo

Northwestern University

Deepika Laddu, PhD

Image of the FSU TMH Family Practice Residency Program in Tallahassee, United States.

Cannabidiol for Diabetic Neuropathy

40 - 70
All Sexes
Tallahassee, FL

The "Cannabidiol for the Treatment of Diabetic Peripheral Neuropathy: Pilot study (CBD-DPN1)" is a double-blinded, placebo-controlled, crossover pilot study evaluating the efficacy of Cannabidiol (CBD) and full-spectrum CBD (fsCBD) tinctures in treating Diabetic Peripheral Neuropathy (DPN)-associated pain. DPN is a common, highly distressing complication of diabetes, characterized by chronic pain and loss of sensory function, for which currently available treatments primarily offer only symptomatic relief. CBD and fsCBD are being investigated for their potential neuroprotective and analgesic effects by regulating inflammation and oxidative stress. The study aims to recruit 12 to 20 adult participants who have mild to moderate DPN. Subjects will receive either an active treatment (CBD isolate or fsCBD in MCT oil, dosed at 50 mg twice daily for a total of 100 mg daily) or a placebo during two sequential 6-week phases. The overall objective of this pilot phase is primarily methodological: to test and refine the clinical protocol, assess patient compliance and acceptability of the CBD formulations, and generate sufficient data to calculate the necessary sample size for a larger, definitive study. Efficacy will be measured using objective and subjective metrics, including DPN severity (DN4 Assessment Tool and DPNCheck™ for nerve conduction velocity) and pain level (PainDetect Questionnaire). Secondary outcomes include evaluating mood (HADS), sleep quality (MOS Sleep Scale), and quality of life (EQ-5D-5L).

Phase 1 & 2
Waitlist Available

the FSU TMH Family Practice Residency Program

Have you considered Cardizem La clinical trials?

We made a collection of clinical trials featuring Cardizem La, we think they might fit your search criteria.
Go to Trials
Image of Grand Island Pain Relief Center in Grand Island, United States.

BurstDR Spinal Cord Stimulation for Diabetic Neuropathy

18+
All Sexes
Grand Island, NE

This prospective, single-arm clinical study evaluates the therapeutic efficacy and feasibility of BurstDR spinal cord stimulation (SCS) using Abbott's Proclaim XR and Eterna systems in patients with painful diabetic neuropathy (PDN). Adults with confirmed PDN will undergo a one-week temporary SCS trial, and those achieving meaningful improvement (≥50% reduction in average pain on the Visual Analog Scale) will proceed to permanent implantation. Outcomes will be assessed at baseline, end of trial, and at 1-, 3-, and 6-month follow-up visits using validated instruments including VAS, DN4, DQoL, PSQ-3, the Patient Global Impression of Change, and the Clinician Global Impression of Change. All procedures follow standard clinical practice for SCS therapy. The study aims to characterize real-world effectiveness, patient-reported outcomes, feasibility of implementation, and device-related safety in a rural PDN population.

Waitlist Available
Has No Placebo

Grand Island Pain Relief Center

TriCity Research Center

Image of Inova Alexandria Hospital in Alexandria, United States.

Heparin Dosing for Blood Clots and Heart Conditions

18+
All Sexes
Alexandria, VA

The goal of this clinical trial study is to test whether a mathematical calculation, using the patient's gender, weight and kidney function, can better predict a patient's heparin goal dose than a flat number of units per patient weight can. Participants will have the first dose of heparin infusion calculated, after which if adjustments are needed, the Hospital's prebuilt table for results driven dosing for this purpose is used. The researchers will compare the time it takes for the participants to get to the desired goal using the patient's information for calculation versus patients in the past who received the medication using the flat rate. The hypothesis is that the patients with enhanced personal data, gender, weight and kidney function, included for the initial dose, will get to their goal lab value sooner and with less chance of delay or overshooting the goal. A quicker time to goal lab value is beneficial to patients in many ways, including earlier treatment of the clot or coronary issue that the patient is experiencing.

Phase 4
Waitlist Available

Inova Alexandria Hospital

Image of U Health in Miami, United States.

Cuffless PPG Monitor for High Blood Pressure

18+
All Sexes
Miami, FL

This study aims to validate the accuracy and reliability of blood pressure (BP) estimates obtained over 24 hours using a PPG-based chest-patch device compared to the gold standard ambulatory blood pressure monitoring (ABPM) method using an upper arm cuff-based oscillometric BP device, in both hypertensive and normotensive individuals referred by their provider to undergo a 24-hours ABPM for clinical indication. The Awake/Asleep test, which is the primary test recommended for automated wearable cuffless BP devices that are cuff-calibrated (based on the 2023 European Society of Hypertension (ESH) recommendations for the validation of cuffless blood pressure measuring devices), will be conducted in this study. The secondary aim of the study is to assess the feasibility and convenience of the PPG-based device.

Waitlist Available
Has No Placebo

U Health (+1 Sites)

Ziad Zoghby, M.D., M.B.A.

Biobeat Technologies Ltd.

Have you considered Cardizem La clinical trials?

We made a collection of clinical trials featuring Cardizem La, we think they might fit your search criteria.
Go to Trials
Image of UPMC Presybeterian in Pittsburgh, United States.

Telaglenastat for Pulmonary Hypertension

18 - 75
All Sexes
Pittsburgh, PA

The research study is being conducted to evaluate the effectiveness of a drug called Telaglenastat in adults diagnosed with Pulmonary Hypertension (PH). PH is a progressive condition that affects the arteries in the lungs, specifically the pulmonary arteries, which carry blood from the right side of the heart to the lungs. Telaglenastat is not currently approved by the Food and Drug Administration for the treatment of PH. However, the study investigators believe that Telaglenastat may help lower blood pressure in the lungs and improve both heart and lung function. It is important to note that the drug will not be available to participants once the study concludes.

Phase 1 & 2
Waitlist Available

UPMC Presybeterian

Michael Risbano, MD

Have you considered Cardizem La clinical trials?

We made a collection of clinical trials featuring Cardizem La, we think they might fit your search criteria.
Go to Trials